Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00088504 · ClinicalTrials.gov registry record · Phase 2

Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

A Phase 2 study of Hepatitis C and Hepatitis, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 2
Development phase
315
Enrollment target
20
Study locations

NCT00088504: Completed Phase 2 study of Hepatitis C and Hepatitis, sponsored by Vertex Pharmaceuticals Incorporated.

NCT00088504 is a Phase 2 study of Hepatitis C and Hepatitis that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 315 participants, below the 1,887-participant average among 106 other Hepatitis C trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00088504, a Phase 2 study of Hepatitis C and Hepatitis, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
315 participants
Enrollment target
20
Study locations

Study Summary

This trial is designed to test whether or not the addition of merimepodib (MMPD) to the standard therapy of pegylated interferon and ribavirin will result in a positive treatment response for people who have not previously responded to this therapy. Approximately 315 subjects will be enrolled in this research study at approximately 55 clinical sites in the United States. There will be three study groups. Everyone in the study will receive Pegasys® (pegylated interferon) and Copegus® (ribavirin) at the normally prescribed doses. Two of the groups will also receive the study drug merimepodib (MMPD) twice a day, one group at each dose level being tested. The third group will take a placebo instead of MMPD, with the Pegasys® and Copegus®. After the first 24 weeks of treatment, blood tests will be done to see if subjects are responding to treatment. If they are responding, they will continue receiving study treatment in the study for another 24 weeks. If they are not responding, they will stop study treatment. Everyone who is responding will be monitored for 24 weeks after the last dose of medication, to see how long the response lasts. Evaluations will be performed during the study to look at the safety of the Pegasys®/Copegus® and MMPD or placebo combination, and to see how the combination is working by measuring Hepatitis C Virus in the blood. At some of the clinical sites performing the study, some subjects may also participate in additional testing to look at the metabolism of the drugs, or to look at the immune response to Hepatitis C virus infection and treatment.

Conditions Studied

Hepatitis C Hepatitis

Interventions

  • DRUG Merimepodib
  • DRUG PEG-Interferon-alpha 2a (Pegasys®)
  • DRUG Ribavirin (Copegus®)

Study Locations (20)

California

  • Michael P. DeMicco, M.D. - Anaheim
  • Prahalad B. Jajodia, M.D. - Fresno
  • F. Fred Poordad, M.D. - Los Angeles
  • Ramsey Cheung, M.D. - Palo Alto
  • Myron J. Tong, M.D., Ph.D. - Pasadena
  • Michael T. Bennett, M.D. - San Diego
  • Lisa M. Nyberg, M.D. - San Diego
  • Natalie Bzowej, M.D. - San Francisco

Illinois

  • Steven L. Flamm, M.D. - Chicago
  • Helen Te, M.D. - Chicago
  • Gerald J. Mingoletti, M.D. - Oak Forest

Alabama

  • Joseph L. Cochran, M.D. - Birmingham
  • Suresh Karne, M.D., Ph.D. - Huntsville

Florida

  • Eugene R. Schiff, M.D. - Miami
  • Jawahar L. Taunk, M.D. - Palm Harbor

Arizona

  • Vijayan Balan, M.D. - Phoenix

Colorado

  • Marcelo Kugelmas, M.D. - Englewood

Connecticut

  • Herbert L. Bonkovsky, M.D. - Farmington

Georgia

  • Arnold L. Lentnek, M.D. - Marietta

Trial Details

FieldValue
Enrollment Target 315 participants
Start Date 2004-07
Est. Completion 2006-10
Phase Phase 2
Vertex Pharmaceuticals Incorporated

191 total trials

What the finished NCT00088504 record still lists

NCT00088504 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 1,887-participant average among 106 other Hepatitis C trials with a reported enrollment target (83% lower).

The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which Merimepodib is the first listed.

NCT00088504 names 20 study sites across 9 states, led by California, Illinois, Alabama.

Frequently Asked Questions

What is clinical trial NCT00088504 about?

NCT00088504 is a clinical study titled "Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C". This trial is designed to test whether or not the addition of merimepodib (MMPD) to the standard therapy of pegylated interferon and ribavirin will result in a positive treatment response for people who have not previously responded to this therapy. Approximately 315 subjects will be enrolled in thi...

What is the current status of trial NCT00088504?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 315 participants. The study started on 2004-07. Estimated completion is 2006-10.

What conditions does trial NCT00088504 study?

This clinical trial studies the following conditions: Hepatitis C, Hepatitis.

What interventions are being tested in trial NCT00088504?

The interventions under investigation include: Merimepodib (DRUG), PEG-Interferon-alpha 2a (Pegasys®) (DRUG), Ribavirin (Copegus®) (DRUG).

Who is sponsoring clinical trial NCT00088504?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00088504 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00088504's enrollment target sits among peer trials

315 34th of 106 higher than 73 of 106 other Hepatitis C trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04812366 · 315 participants · Phase 2

    Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

  • NCT05101460 · 315 participants

    An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant

  • NCT05897320 · 315 participants · Phase 3

    A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

  • NCT06439082 · 315 participants · Phase 3

    A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00088504, the US trial registry maintained by the National Library of Medicine. NCT00088504 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.